Patents by Inventor Somya Kapoor
Somya Kapoor has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230105757Abstract: The present invention relates to a process of removing free-unlabeled radionuclides from a radiopharmaceutical prior to administering the radiopharmaceutical to the patient using size-exclusion or ion-exchange mechanisms.Type: ApplicationFiled: November 10, 2022Publication date: April 6, 2023Applicant: UNIVERSITY OF IOWA RESEARCH FOUNDATIONInventors: Michael K. Schultz, Somya Kapoor, Douglas R. Spitz
-
Patent number: 11596613Abstract: The invention provides compositions and methods to treat a hyperproliferative disorder with a GSH synthesis inhibitor and an anti-cancer composition.Type: GrantFiled: July 31, 2020Date of Patent: March 7, 2023Assignee: UNIVERSITY OF IOWA RESEARCH FOUNDATIONInventors: Michael K. Schultz, Somya Kapoor, Douglas R. Spitz
-
Patent number: 11576987Abstract: The invention provides compositions, kits and methods to treat a hyperproliferative disorder with an agent that increases expression of MCR1 and an MCR1 ligand. The invention also provides a method of treating drug-resistant melanoma, comprising administering an MCR1 ligand to a patient in need thereof. The present invention also provides in certain embodiments a melanoma-targeting conjugate comprising Formula I: T-L-X wherein T is a MCR1 ligand, L is a linker, and X an anti-cancer composition, for the therapeutic treatment of a hyperproliferative disorder. The present invention also provides methods, kits and uses of the conjugate of Formula I.Type: GrantFiled: October 21, 2021Date of Patent: February 14, 2023Assignee: UNIVERSITY OF IOWA RESEARCH FOUNDATIONInventors: Michael K. Schultz, Frances L. Johnson, Somya Kapoor, Dongyoul Lee, Mengshi Li, Molly Martin
-
Patent number: 11529335Abstract: The invention provides compositions and methods to treat a hyperproliferative disorder with a GSH synthesis inhibitor and an anti-cancer composition.Type: GrantFiled: July 31, 2020Date of Patent: December 20, 2022Assignee: UNIVERSITY OF IOWA RESEARCH FOUNDATIONInventors: Michael K. Schultz, Somya Kapoor, Douglas R. Spitz
-
Publication number: 20220111080Abstract: The invention provides compositions, kits and methods to treat a hyperproliferative disorder with an agent that increases expression of MCR1 and an MCR1 ligand. The invention also provides a method of treating drug-resistant melanoma, comprising administering an MCR1 ligand to a patient in need thereof. The present invention also provides in certain embodiments a melanoma-targeting conjugate comprising Formula I: T-L-X wherein T is a MCR1 ligand, L is a linker, and X an anti-cancer composition, for the therapeutic treatment of a hyperproliferative disorder. The present invention also provides methods, kits and uses of the conjugate of Formula I.Type: ApplicationFiled: October 21, 2021Publication date: April 14, 2022Applicant: UNIVERSITY OF IOWA RESEARCH FOUNDATIONInventors: Michael K. Schultz, Frances L. Johnson, Somya Kapoor, Dongyoul Lee, Mengshi Li, Molly Martin
-
Publication number: 20220072092Abstract: The invention provides compositions, kits and methods to treat a hyperproliferative disorder with an agent that increases expression of MCR1 and an MCR1 ligand. The invention also provides a method of treating drug-resistant melanoma, comprising administering an MCR1 ligand to a patient in need thereof. The present invention also provides in certain embodiments a melanoma-targeting conjugate comprising Formula I. T-L-X wherein T is a MCR1 ligand, L is a linker, and X an anti-cancer composition, for the therapeutic treatment of a hyperproliferative disorder. The present invention also provides methods, kits, and uses of the conjugate of Formula I.Type: ApplicationFiled: November 19, 2021Publication date: March 10, 2022Applicant: UNIVERSITY OF IOWA RESEARCH FOUNDATIONInventors: Michael K. Schultz, Frances L. Johnson, Somya Kapoor, Dongyoul Lee, Mengshi Li, Molly Martin
-
Publication number: 20220031674Abstract: The invention provides compositions and methods to treat a hyperproliferative disorder with a GSH synthesis inhibitor and an anti-cancer composition.Type: ApplicationFiled: July 31, 2020Publication date: February 3, 2022Inventors: Michael K. Schultz, Somya Kapoor, Douglas R. Spitz
-
Patent number: 11179484Abstract: The invention provides compositions, kits and methods to treat a hyperproliferative disorder with an agent that increases expression of MCR1 and an MCR1 ligand. The invention also provides a method of treating drug-resistant melanoma, comprising administering an MCR1 ligand to a patient in need thereof. The present invention also provides in certain embodiments a melanoma-targeting conjugate comprising Formula (I): T-L-X wherein T is a MCR1 ligand, L is a linker, and X an anti-cancer composition, for the therapeutic treatment of a hyperproliferative disorder. The present invention also provides methods, kits and uses of the conjugate of Formula (I).Type: GrantFiled: June 26, 2017Date of Patent: November 23, 2021Assignee: UNIVERSITY OF IOWA RESEARCH FOUNDATIONInventors: Michael K. Schultz, Frances L. Johnson, Somya Kapoor, Dongyoul Lee, Mengshi Li, Molly Martin
-
Publication number: 20210113503Abstract: The invention provides compositions and methods to treat a hyperproliferative disorder with a GSH synthesis inhibitor and an anti-cancer composition.Type: ApplicationFiled: July 31, 2020Publication date: April 22, 2021Inventors: Michael K. Schultz, Somya Kapoor, Douglas R. Spitz
-
Patent number: 10729669Abstract: The invention provides compositions and methods to treat a hyperproliferative disorder with phenyl butyric acid (PBA) or a pharmaceutically acceptable salt thereof and an anti-cancer composition.Type: GrantFiled: July 26, 2016Date of Patent: August 4, 2020Assignee: University of Iowa Research FoundationInventors: Michael K. Schultz, Somya Kapoor, Andrean L. Simons-Burnett
-
Publication number: 20200147060Abstract: The invention provides in certain embodiments a therapeutic regimen comprising (a) an anti-cancer combination of vemurafenib and cobimetinib, or a combination of trametinib and dabrafenib, and (b) a secondary agent comprising L-buthionine-[S,R]-sulfoximine (BSO), or phenyl butyric acid (PBA) or a pharmaceutically acceptable salt thereof, and chloroquine or hydrochloroquine (HCQ) for the therapeutic treatment of a hyperproliferative disorder.Type: ApplicationFiled: October 30, 2019Publication date: May 14, 2020Applicant: UNIVERSITY OF IOWA RESEARCH FOUNDATIONInventors: Michael K. Schultz, Somya Kapoor, Douglas R. Spitz, Andrean Burnett, Ling Yang
-
Publication number: 20190321495Abstract: The invention provides compositions, kits and methods to treat a hyperproliferative disorder with an agent that increases expression of MCR1 and an MCR1 ligand. The invention also provides a method of treating drug-resistant melanoma, comprising administering an MCR1 ligand to a patient in need thereof. The present invention also provides in certain embodiments a melanoma-targeting conjugate comprising Formula (I): T-L-X wherein T is a MCR1 ligand, L is a linker, and X an anti-cancer composition, for the therapeutic treatment of a hyperproliferative disorder. The present invention also provides methods, kits and uses of the conjugate of Formula (I).Type: ApplicationFiled: June 25, 2017Publication date: October 24, 2019Applicant: UNIVERSITY OF IOWA RESEARCH FOUNDATIONInventors: Michael K. Schultz, Frances L. Johnson, Somya Kapoor, Dongyoul Lee, Mengshi Li
-
Publication number: 20180214402Abstract: The invention provides compositions and methods to treat a hyperproliferative disorder with phenyl butyric acid (PBA) or a pharmaceutically acceptable salt thereof and an anti-cancer composition.Type: ApplicationFiled: July 26, 2016Publication date: August 2, 2018Applicant: UNIVERSITY OF IOWA RESEARCH FOUNDATIONInventors: Michael K. Schultz, Somya Kapoor, Andrean L. Simons-Burnett
-
Publication number: 20170290929Abstract: Accordingly, certain embodiments of the invention provide a conjugate of formula (I): P-(X-D)n, wherein P is a peptide that binds to a glucose regulated protein 78 (GRP78); X is a direct bond or a linking group; D is a detectable agent; and n is 1 to 4. Certain embodiments of the invention provide a pharmaceutical composition comprising a conjugate of formula (I) and a pharmaceutically acceptable excipient. Certain embodiments of the invention provide a method for treating or preventing cancer in an animal (e.g., a human) comprising administering a therapeutically effective amount of a conjugate of formula (I) (e.g., a conjugate comprising a therapeutic radionuclide) to the animal.Type: ApplicationFiled: May 14, 2015Publication date: October 12, 2017Applicant: University of Iowa Research FoundationInventors: Somya Kapoor, Michael K. Schultz